BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200224
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T060818
CREATED:20191016T074751Z
LAST-MODIFIED:20191017T085729Z
UID:22867-1582502400-1582847999@www.pharmajournalist.com
SUMMARY:CAR-TCR Europe Summit
DESCRIPTION:With CAR-T therapies on the cusp of achieving global approval\, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for. The CAR-TCR Europe Summit will unravel the technical challenges across translation\, scale and delivery to provide your team with the platform to learn\, collaborate and gain actionable insights to advance your therapy for clinical and commercial success. \nThis focused agenda will delve into the technical bottlenecks encountered in every stage of the CAR-TCR drug development cycle\, providing a comprehensive analysis across 3 tracks including: Translational\, Manufacturing & Clinical \nTo learn more about CAR-TCR Europe Summit and to register online\, visit https://ter.li/9iuqer
URL:https://www.pharmajournalist.com/event/car-tcr-europe-summit/
LOCATION:Novotel London West\, Hammersmith\, London\, W6 8DR
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T060818
CREATED:20191016T073714Z
LAST-MODIFIED:20191017T085556Z
UID:22862-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:3rd Antigen Specific Immune Tolerance Summit
DESCRIPTION:Translating Emerging Antigen Specific Immune Tolerance Approaches for Therapeutic Applications \nAccelerate the progression of ethical and effective antigen specific immunotherapies through the clinic\, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing combination therapies. \n \nBuilding on the success of the 2019 meeting\, the 3rd Antigen Specific Immune Tolerance Summit (ASIT) returns to Boston on February 25-27\, 2020. The meeting will bring together industry representatives from the fields of autoimmunity\, allergy\, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies\, ASIT 2020 is the only antigen specific summit offering thought leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. \n\nHear from and engage with a world-class speaking faculty made up of 26 industry representatives including Novo Nordisk\, Pfizer\, Merck\, Eli Lilly\, ITN & FDA\nExplore cross learning opportunities from parallel fields tackling immune tolerance and better understand the fundamental mechanisms that lie behind tolerance induction\nEngage with and immerse yourself within a learning journey across three conference days\, tackling all elements of drug development from discovery to clinical development\nGain practical insight from those describing recent clinical trials and determine what mechanisms lie behind successful and unsuccessful clinical trials\nEmploy novel therapeutics in combination with antigen specific immunotherapies and drive the progression of drug development towards the clinic\nTake advantage of intimate networking opportunities with key opinion leaders from large pharma\, biotech and academia through discursive and engaging platforms that spark conversation and debate\n\nTo learn more about 3rd Antigen Specific Immune Tolerance Summit and to register online\, visit https://ter.li/rp07a3
URL:https://www.pharmajournalist.com/event/3rd-antigen-specific-immune-tolerance-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T060818
CREATED:20191215T123515Z
LAST-MODIFIED:20191215T123645Z
UID:23340-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:RAS- Targeted Drug Discovery Summit Europe
DESCRIPTION:After three decades of trial and error to target the driver of 30% of all diagnosed cancers\, scientists are finally making meaningful clinical progression to target the cancer master switch\, the RAS family of proteins. \n \nThe RAS- Targeted Drug Discovery Summit Europe is the only industry-led and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science\, capturing the most pioneering data\, thought-provoking insights and practical lessons learned\, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins\, gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic. Hear from the likes of Boehringer Ingelheim\, Sanofi\, Bayer\, Francis Crick Institute\, PhoreMost\, Allinky Biopharma\, Elicio Therapeutics\, Oblique Therapeutics\, Onconova Therapeutics and Revolution Medicines. Visit the website to see the full speaker line-up\, what will be discussed\, pricing and ticket options: https://ter.li/8qb2rr.
URL:https://www.pharmajournalist.com/event/ras-targeted-drug-discovery-summit-europe/
LOCATION:Hilton Vienna Plaza\, Schottenring 11\, Vienna\, A - 1010\, Austria
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T060818
CREATED:20200110T081422Z
LAST-MODIFIED:20200110T081422Z
UID:23647-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:8th Neurodegenerative Drug Development Summit
DESCRIPTION:Returning to Boston in February 2020 is the 8th Neurodegenerative Drug Development Summit\, previously World CNS. \nDespite the lack of clinical trial success\, new investments are being made in forward-thinking biotechs\, digital and blood-based biomarker technologies are advancing\, new targets are emerging\, and gene therapy is taking the limelight. \nThe Neurodegenerative Drug Development Summit will unite industry stakeholders to learn how to overcome their translational challenges\, share their progress and network for future collaborations to accelerate the development of successful neurodegenerative therapeutics. \nDon’t miss your opportunity to join over 150 fellow CNS experts from Biogen\, AbbVie\, Sanofi and more\, and immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.
URL:https://www.pharmajournalist.com/event/8th-neurodegenerative-drug-development-summit/
LOCATION:Hyatt Regency Boston\, 1 Avenue de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200226
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T060818
CREATED:20200217T092303Z
LAST-MODIFIED:20200217T092639Z
UID:24192-1582675200-1582847999@www.pharmajournalist.com
SUMMARY:21st Pharmacovigilance 2020
DESCRIPTION:“Latest developments in pharmacovigilance\, drug safety and RMP” \n21st Pharmacovigilance 2020 event keeps an immersed eye on discussion of critical topics in PV domain\, which capture influence of emerging technologies like AI\, IoT\, Big Data. Not merely that\, we have exciting surprise activities which will help you to interact more with your peers. This will be surely an exciting event wherein you could get chance to meet big industry gems. Let’s gather to shape the industry with your magnificent ideas. \n \nSPONSORS: \n\nCovance\nBrookwood Global\n\nWe also have more sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/Booth/Stall and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. \nDELEGATE REGISTRATION: \nIn order to register please contact us on Email: kavitha@virtueinsight.co.in   \n1 Delegate @ £1299 + VAT \n3 Delegates @ £2598 + VAT \nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/21st-pharmacovigilance-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
END:VCALENDAR